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Background: 
 
An 80 year old man with advanced Parkin-
son’s disease (PD) was admitted to the neu-
roscience unit with a worsening decline in 
mobility. Medical management was the com-
mencement and titration of the levodopa-
carbidopa intestinal gel (LCIG) Duodopa ® 
via a naso-jejunal tube, which had been in-
serted under fluoroscopy in Interventional 
Radiology. Over a ten day trial period the pa-
tient responded well to the administration of 
the LCIG with much less periods of difficulty 
with movement (known as OFF times) alt-
hough he did continue to experience periods 
of dyskinesia, some paranoid behaviours and 
notable episodes of ‘punding’ (repetitive non-
purposeful movements). Following these 
promising results from the LCIG infusion, the 
patient consented to proceed to the insertion 
of a direct jejunostomy for permanent trans-
jejunal intestinal infusion by a upper gastroin-
testinal surgeon. On day 2 post insertion of 
the jejunostomy tube the patient complained 
of nausea and vomiting and overnight he was 
transferred to the intensive care unit (ICU) 
with a suspected bowel obstruction and an 
aspiration pneumonia.  
 
 
 
 
 
 
 
 
Do the benefits of Duodopa eclipse the 
complications? 
 
Duodopa ® has been increasingly accepted 
as an effective treatment for troublesome mo-
tor fluctuations and dyskinesia for patients 
with advanced Parkinson’s Disease (Lang et 
al., 2016; Nyholm et al., 2008; Olanow et al., 
2014).Oral administration of levodopa leads 
to variable plasma levels from erratic gastric 
emptying (Nyholm et al., 2008).The intraduo-
denal delivery of levodopa connected to a 
portable pump provides a relatively steady 
plasma level of levodopa (Chang et al. 2016).    
The usual delivery of LCIG is via a percutane-
ous endoscopic gastrostomy/ jejunostomy 
tube (PEG/J). This system uses a percutane-
ous gastrostomy tube with fine bore jejunal 
extension, so that the gel can be directly in-
fused into the jejunum where absorption of 
the medication will be  optimized (Tsui, 2014). 
For the  patients the neurologists opted for 
the insertion of a direct jejunostomy tube, with 
the placement of the tube directly into the 
small intestine for the administration of the 
gel. This decision was based on the reported 
complications associated with the PEG/J de-
livery system (Kimber & Shoeman (2014). It 
also highlighted the notion that persistence in 
focusing on the clinical benefits of Duodopa 
has the potential to eclipse the challenges 
and complications of introducing a new jeju-
nostomy tube for patients with an already de-
bilitating disease (Bianco et al., 2012).  
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Complications related to the use of the 
PEG/J tube: 
 
Within the studies on the benefits of Duodopa 
are reports of tube/stoma complications. Ny-
holm et al (2008) reports the most common 
complication for the PEG/J tube was disloca-
tion of the tube from the small intestine to the 
stomach. Another two studies noted that the 
main safety issue of the LCIG related to the 
infusion system with technical problems as-
sociated with kinking and blocking of the tube 
(Senek & Nyholm, 2014; Zibetti et al., 2014). 
Zibetti et al (2014) reported one duodenal 
perforation out of 59 patients, while Kimber & 
Shoeman (2014) report two gastric perfora-
tions out of 17 patients which required lapa-
rotomy to repair. Recurrent minor problems 
were  tube malfunction and dislocation sec-
ondary to punding (Chang et al., 2016).  A 
constantly dislodged tube requires repeated 
re-siting of the jejunal tube (Foltynie et al., 
2013), which exposes patients to a return to 
the endoscopy suite  and the increased risks 
of hospitalization and general anaesthesia 
(Kimber & Schoeman, 2014). 
 
Complications are also related to infection 
around the stoma, (van Laar, Nyholm, & Ny-
man, 2016) with reports of excessive granu-
lation tissue, incision site erythema, ab-
dominal pain, peritonitis and pneumoperito-
neum (Fernandez et al., 2015; Zibetti et al., 
2014). Zibetti et al (2014) noted infection 
tended to occur within one month of the PEG/
J procedure and were successfully treated 
with antibiotic therapy, however device com-
plications were the contributing reason for 
discontinuation of the infusion for a propor-
tion of patients. 
 
A study of 85 patients undergoing Duodopa 
infusion was conducted regarding nutritional 
status and weight loss in patients and deter-
mined that those without tube complications 
had significant weight gain over a 6 month 
period (Galletti et al., 2011). 
Major complications of PEG/J - Buried 
Bumper Syndrome:  
 
Buried bumper syndrome (BBS) occurs when 
there is an overgrowth of the gastric mucosa 
over the inner bumper of the gastrostomy 
tube. Predisposing factors for BBS are tight 
fitting gastrostomy tubes, weight gain and no 
mobilization of the tube for the first month 
(Santos García et al., 2016). BBS was report-
ed to have a higher incidence of occurrence 
in Freka PEG tubes (which is the preferred 
PEG/J tube for Duodopa),  compared with a 
Corflo PG tube in one study (Dowman et al., 
2015). Although another similar sized study 
claims a low incidence of BBS from Freka 
tubes published in October this year (Clarke 
& Lewis, 2016). Notably both studies exam-
ined the incidence of BBS in PEG/J tube that 
had been required for the purposes of enteral 
feeding and not for Duodopa administration. 
Bezoars and Phytobezoars: 
 
Bezoars are composed of undigested food 
material that has been orally ingested 
(Altintoprak et al., 2012) and are classiﬁed 
based on the type of material they contain.  
Phytobezoars are described as occurring in 
patients who consume high amounts of fi-
brous and long fibre foods such as aspara-
gus or spinach that may be difficult to digest 
(Altintoprak et al. 2012). In a case of a 21 
year old male who had received LCIG for 6 
months a blockage of his tubing was discov-
ered  to be jejunal tube being knotted in the 
stomach around a bezoar (Negreanu et al., 
2010). 
 
 A 70 year old man presented with abrupt 
motor deterioration from tube obstruction 
from a bezoar. He was treated with a liquid 
diet and the use of Coca-Cola ® over four 
days until the bezoar was successfully dis-
solved (Stathis, Tzias, Argyris, Barla, & 
Maltezou, 2014). 
 In another case it was reported that a phy-
tobezoar entrapped the tip of a 71 year old 
male patient’s jejunal tube and resulted in a 
jejunal wall perforation and fistulisation of 3 
intestinal loops. Unfortunately the patient was 
reported to have died post-operatively follow-
ing repair of the fistula (Vuolo et al., 2012). 
Given the non-motor symptoms of Parkin-
son’s disease that include poor gut motility 
and constipation (Fasano, Visanji, Liu, Lang, 
& Pfeiffer, 2015) it would seem that the risk of  
bezoars would be higher when coupled with  
reduced gastrointestinal motility caused by 
the PEG/J.  
 
A long term PEG/J study determined that the 
procedural outcomes and adverse rates in 
patients treated using the PEG-J drug deliv-
ery system were acceptable,  and that bene-
fits of the therapy outweighed these compli-
cations (Epstein et al., 2016). Kimber & 
Shoeman (2104) felt that the high number of 
PEG/J complications was justification to intro-
duce the use of the DEJ tube.  
Small bowel obstruction secondary to Je-
junostomy tube: 
 
An abdominal CT scan reported that our 80 
year old patient had a jejunal obstruction due 
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to kinking at the level of the jejunostomybal-
loon; a distended stomach and fluid filled oe-
sophagus, with consolidation in the lung ba-
ses secondary to aspiration. The balloon of 
the jejunal tube was deflated and a Salem 
sump nasogastric tube was inserted. Blood 
cultures returned an Enterobacter bacterae-
mia which was treated with IV antibiotics. He 
was given a beta-blocker for a new onset of 
atrial fibrillation secondary to his aspiration 
pneumonia and returned to the ward after 3 
days in ICU. Once on the ward a new jeju-
nostomy tube was inserted under fluoroscopy 
and sutured into place, following dislodge-
ment of the first Jejunostomy without the bal-
lon inflated for securement of the tube. He 
was restarted on the LCIG again with good 
motor results, less punding and no further 
hallucinations or paranoia. Two days after 
insertion of the second Jejunostomy tube, 
oozing around the tube necessitated review 
by the Stoma Clinical Nurse Consultant and 
the placement of an ileostomy bag. He was 
eventually discharged to a rehabilitation hos-
pital and eighteen months later the patient 
reports fluctuations in the amount of ooze/
leaks around the stoma site, which is tempo-
rarily alleviated with reductions in faecal load-
ing through the use of regular aperients.  
PEG, PEG/J and Jejunostomy tubes: 
 
The nurses on the neurological ward are fa-
miliar with percutaneous endoscopic jejunos-
tomy (PEG) tubes which are used routinely 
for enteral nutrition for patients at high risk of 
aspiration typically following stroke or trau-
matic brain injury. PEG/J feeding tubes are 
rarely used on our ward, but were reported to 
be developed for jejunal feeding to reduce 
gastroesophageal reflux occurring in PEG 
feeding. These tubes presented new chal-
lenges with PEG/J malfunction due to clog-
ging and proximal migration of the extension 
tube back into the stomach (Panagiotakis, 
DiSario, Hilden, Ogara, & Fang, 2008), which 
was also noted in the studies for Duodopa. 
The same authors studied the benefit of a 
direct percutaneous endoscopic jejunostomy 
tube (DPEJ) to PEG/J and determined in a 
retrospective study of 75 patients a decrease 
in the overall incidence of aspiration pneumo-
nia. 
 
A search of the hospital’s protocol on PEG 
and jejunostomy tube returned guidelines for 
the role in enteral nutrition only with limited 
information for the care of a direct Jejunosto-
my for the sole purpose of medication admin-
istration. A search on CINAHL to compare 
rates of complications between DEJ to PEG/J 
retrieved only one retrospective study of 560 
patients where the tubes were used for the 
purposes of enteral feeding indicated in pa-
tients with GIT / Head and Neck cancers, 
Stroke and other neurologic conditions which 
were not specifically identified (Ao, Sebas-
tianski, Selvarajah, & Gramlich, 2015). Ao et 
al. (2015) concluded that there was a higher 
risk of tube related complications, particularly 
the requirement of tube replacement in the 
patients with the DEJ tubes (48.4%) than that 
of the PEG group (21.5%). To date the only 
other study which directly compares the two 
devices is a small study of 17 patients for 
Duodopa ® infusion where the authors advo-
cated DEJ as a feasible alternative to the 
PEG/J tubes. This study reported a lower 
incidence in tube malfunction when compar-
ing 8 patients undergoing PEG/J to 9 patients 
who received DEJ devices (Kimber & Schoe-
man, 2014).  
 
Conclusion: 
 
The administration of the LCIG has provided 
patients with advanced Parkinson’s disease 
with great benefits in motor fluctuations and 
dyskinesia. The delivery of the intestinal gel 
requires an invasive PEG/J tube which brings 
a new set of challenges for these patients 
and the nurses caring for them.  There is a 
lack of compelling evidence to support the 
introduction of the direct Jejunostomy tube 
having greater benefits, as opposed to the 
PEG/J. Further future studies are warranted 
not only to compare the safety and the rates 
of complications between the two devices, 
but also to increase knowledge and develop 
sound protocols for patients/families and 
nursing staff when using the direct Jejunosto-
my device to reduce complications and ad-
verse outcomes. 
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